ArticlePhotochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology2026
Investigation of the impact of D, L-methadone on ALA-PDT in multiple glioblastoma cell lines.
Article in Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor, characterized by infiltrative growth, resistance to chemotherapy and radiotherapy, and an immune-suppressive microenvironment. Interstitial Photodynamic Therapy (iPDT), which involves oral ALA administration and localized light activation, offers a promising approach by killing tumor cells, disrupting tumor vasculature, and stimulating the immune response. However, iPDT faces limitations due to the blood-brain barrier (BBB), insufficient irradiation of satellite and margin tumors, hypoxia within the tumor microenvironment, and glioma cell repair mechanisms. These factors collectively contribute to the suboptimal efficacy of iPDT, emphasizing the need for combined therapeutic strategies to improve outcomes. Some in-vitro research on D, L-methadone, which enhances chemotherapy and ALA-PDT, has caught our interest, although it remains controversial.
methodsThe levels of the μ-opioid receptor (MOR) were measured in multiple GBM cell lines. Multiple GBM cell lines (A172, U251, GB14) were treated with 2.5 µg/ml and 10 µg/ml D, L-methadone in combination with sublethal-dose ALA-PDT to mimic the limitations of PDT. A MOR antagonist, naloxone (NAL), was used to inhibit the potential role of methadone. Cell viability, apoptosis, PpIX, and ROS were examined.
resultsThe expression level of MOR in GBM cell lines was low. In the A172 cell line, 10 µg/ml methadone enhanced sublethal-dose ALA-PDT-induced apoptosis; however, in the U251 and GB14 cell lines, neither 2.5 µg/ml methadone nor 10 µg/ml methadone could enhance ALA-PDT-induced apoptosis. The viability of the three cell lines was unaffected by methadone combined with ALA-PDT. No reversal effect of naloxone on methadone was observed. Data show that methadone did not significantly enhance PpIX accumulation or ROS generation when combined with ALA-PDT.
conclusionsA general sensitizing effect of methadone on ALA-PDT was not observed in this in vitro experiment involving multiple GBM cell lines. The sensitizing effect of methadone on ALA-PDT may depend on the specific cell line used. Therefore, the recommendation to use methadone as a sensitizer for ALA-PDT in the treatment of GBM should be made with caution.
Indexed as
Identifiers
41811650What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.